Lyndsey Whitaker, APRN
Family · Fayetteville, ARNPI 1295292332
Payments from drug & device makers
Across 121 payments — averaging $22.72 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$688
- Sanofi$424
- Lilly USA, LLC$399
- Johnson & Johnson$325
- LEO Pharma Inc.$240
- UCB, Inc.$126
- plus $548 from 12 others
What the payments were for
- Food & beverage$2,64196%
- Education$1084%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 40 | $688 |
| Sanofi | 9 | $424 |
| Lilly USA, LLC | 20 | $399 |
| Johnson & Johnson | 9 | $325 |
| LEO Pharma Inc. | 11 | $240 |
| UCB, Inc. | 7 | $126 |
| Novartis | 2 | $107 |
| Sun Pharmaceutical Industries Inc. | 4 | $100 |
| Amgen | 4 | $94 |
| Redhill Biopharma Inc. | 4 | $69 |
| Novo Nordisk | 3 | $47 |
| Biofrontera Inc. | 2 | $39 |
| Ortho Dermatologics, A Division Of Bausch Health US, LLC | 1 | $20 |
| Pfizer | 1 | $19 |
| Regeneron Healthcare Solutions, Inc. | 1 | $19 |
| W. L. Gore & Associates, Inc. | 1 | $14 |
| Endo Pharmaceuticals Inc. | 1 | $13 |
| Organon | 1 | $5 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Skyrizi$244
- DUPIXENT$235
- Tremfya$145
- SIMPONI ARIA$145
How this compares
$2,750 in reported general payments places this provider in the 85th percentile of 2,103 family providers in Arkansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Clobetasol Propionate | 31 | $770 |
| Clindamycin Phosphate | 13 | $687 |
| Ketoconazole | 18 | $264 |
| Pantoprazole Sodium | 30 | $241 |
| Mupirocin | 26 | $189 |
| Triamcinolone Acetonide | 21 | $185 |
| Omeprazole | 17 | $110 |
Paid to pharmacies, not to this prescriber.
Other family in Fayetteville
- Shelby CochranFayetteville$23K
- Margaret OliverFayetteville$12K
- Christopher TitsworthFayetteville$9K
- Leah CarringtonRogers$1.6M
- Nina CopelandFort Smith$207K
- Stefanie BrackinJonesboro$51K
- Amanda DavisFort Smith$46K
- Allison HittManila$40K
- Kimberly GatesNorth Little Rock$31K
- Meghan MallettConway$25K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.